ITEMS OF INTEREST TO THE IMAGING RESEARCH COMMUNITY:
CIP Web Site: http://www.cancer.gov/bip
- PLANNING GRANTS: IN VIVO CELLULAR AND MOLECULAR IMAGING CENTERS (PRE-ICMICs) - NCI (CA-01-010)
Letter of Intent Receipt Date: July 14, 2000; Application Receipt Date: August 18, 2000
The Biomedical Imaging Program, Division of Cancer Diagnosis and Treatment of the National Cancer Institute (NCI) invites applications for P20 planning grants that lead to the establishment of In Vivo Cellular and Molecular Imaging Centers. This Request for Applications (RFA) invites applications for P20 Planning Grants. Applicants should note that NCI anticipates the re-issuance of an RFA (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-99-004.html) to invite applications for P50 Center grants. While the NCI plans to proceed with the P50 initiative, its publication and timing is not yet certain and depends on sufficient funds being available.
OTHER GOVERNMENT AGENCIES
- DEPARTMENT OF DEFENSE OVARIAN CANCER RESEARCH PROGRAM - DOD SOL CBD-OCR-0428 D
UE Septembr 13, 2000
POC Craig D. Lebo, Contracting Officer, 301-619-2036.
The Fiscal Year (FY) 2000 Defense Appropriations Act provides $12M to continue the Department of Defense Ovarian Cancer Research Program (OCRP) administered by the U.S. Army Medical Research and Materiel Command through the Congressionally Directed Medical Research Programs (CDMRP). The OCRP is seeking meritorious research focused on epithelial ovarian carcinoma and/or primary peritoneal carcinoma. Emphasis on one or more of the following research areas is encouraged: (1) etiology, (2) early detection/diagnosis, (3) preclinical therapeutics, and (4) quality of life. The programmatic strategy for the OCRP FY00 is to fund proposals through two research award mechanisms: Ovarian Cancer New Investigator Awards and Program Project Awards.
The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.
If you wish to remain on the list, no action is necessary. If you wish to be added to the list (or removed from it), please contact Ms. Johnnie Smith by return e-mail (firstname.lastname@example.org).
Cancer Imaging Program
Division of Cancer Treatment and Diagnosis, NCI
EPN, Room 6000 - MSC-7412
6130 Executive Boulevard
Bethesda, MD 20892-7440
Tel: 301 496 9531
Fax: 301 480 3507